IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i3d10.1007_s40264-022-01146-7.html
   My bibliography  Save this article

Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports

Author

Listed:
  • Camille Azam

    (Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, CIC 1436, CHU, Université de Toulouse)

  • Louis Buscail

    (Service de Gastroentérologie et Pancréatologie, CIC Biotherapies 1436, CHU, Université de Toulouse)

  • Adrian Culetto

    (Service de Gastroentérologie et Pancréatologie, CHU, Université de Toulouse)

  • Maryse Lapeyre-Mestre

    (Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, CIC 1436, CHU, Université de Toulouse)

Abstract

Introduction In addition to the growing interest of different cannabinoids for therapeutic purposes, the safety profile of these substances has changed, with the recent identification of new events such as acute pancreatitis. Objective The aim of this study was to characterize cannabinoid-related acute pancreatitis, based on the recent literature and the analysis of pharmacovigilance data available worldwide. Methods Nine national and international pharmacovigilance databases were requested for individual case safety reports of acute pancreatitis related to cannabinoid exposure. A systematic review was performed searching in PubMed®, Web of Science®, and Google Scholar® for any publication dealing with acute pancreatitis and cannabinoid exposure (cannabis, cannabinoid, cannabidiol, tetrahydrocannabinol, nabilone, dronabinol), to identify case reports, observational studies, clinical trials, or reviews. All queries were updated on 1 January, 2021. Results Twenty-two individual case safety reports were identified in the pharmacovigilance databases and 51 in the literature, corresponding to a predominantly young male population (74% of men, median age 28 interquartile range [21–39]) using recreational Cannabis sativa with high intensity. A therapeutic purpose was identified in 13 cases (including tetrahydrocannabinol, cannabidiol, and dronabinol). The outcome was often favorable after dechallenge (except three deaths), and frequent recurrences were observed in the case of rechallenge or sustained consumption. Eleven cross-sectional studies and one ecological study showed an increasing trend of cannabis use in in-patients with acute pancreatitis, with a significantly lower in-hospital mortality. Conclusions This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use. It remains often unrecognized and can occur during recreational or therapeutic use. The development of the therapeutic use of cannabinoids in frail patients deserves a better investigation of the benefit-risk ratio of these different products.

Suggested Citation

  • Camille Azam & Louis Buscail & Adrian Culetto & Maryse Lapeyre-Mestre, 2022. "Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports," Drug Safety, Springer, vol. 45(3), pages 215-235, March.
    • Handle: RePEc:spr:drugsa:v:45:y:2022:i:3:d:10.1007_s40264-022-01146-7
    DOI: 10.1007/s40264-022-01146-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01146-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-022-01146-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Thomas Berbain & Antoine Pariente & Ghada Miremont-Salamé & Aurélie Grandvuillemin & Joelle Micallef & Laurent Chouchana & Mehdi Benkebil & Hélène Théophile, 2020. "Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database," Drug Safety, Springer, vol. 43(3), pages 243-253, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:3:d:10.1007_s40264-022-01146-7. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.